13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001782539
Total reported value
$131.5M
$131.5M
24 檔
63.0%
According to the latest 13F quarterly dataset, Nan Fung Group Holdings Ltd managed an equity portfolio of $131.5M at the end of Q1 2026, spanning 24 distinct U.S. exchange-listed positions.
In Q1 2026, Nan Fung Group Holdings Ltd adopted a defensive or profit-taking posture, trimming 4 positions and completely liquidating 5 holdings to manage risk exposure.
In terms of portfolio concentration, the top 5 core holdings (including EVMN, MPLT, LBRX) accounted for 63.0% of total reported equity market value during Q1 2026.
Top New Position Initiated
CELC
市值: $3.2M
Top Position Liquidated / Trimmed
LAB
前期市值: $2.4M
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | EVMN | Evommune Inc | Stock-Other | 27.32% | -12.76% | — | |
| 2 | MPLT | Maplight Therapeutics Inc | Stock-Other | 16.28% | +10.19% | — | |
| 3 | LBRX | Lb Pharmaceuticals Inc | Stock-Other | 12.82% | +2.75% | +110.22% | |
| 4 | OCS | Oculis Holding AG | Stock-Other | 7.69% | -4.52% | -31.85% | |
| 5 | INCY | Incyte CORP | Stock-Healthcare | 4.17% | +0.46% | -8.95% | |
| 6 | ONC | Beone Medicines Ltd-adr | Stock-Other | 3.85% | -0.44% | — | |
| 7 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 3.52% | +0.63% | — | |
| 8 | CELC | Celcuity Inc | Stock-Other | 2.66% | -0.41% | — | |
| 9 | ASND | Ascendis Pharma A/S | Stock-Other | 2.57% | -2.57% | EXIT | |
| 10 | PCOR | Procore Technologies Inc | Stock-Tech | 2.51% | -0.86% | — | |
| 11 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 2.45% | -0.13% | -52.22% | |
| 12 | KYMR | Kymera Therapeutics Inc | Stock-Other | 2.12% | +0.57% | — | |
| 13 | ACAD | Acadia Pharmaceuticals Inc | Stock-Healthcare | 1.89% | +0.09% | — | |
| 14 | HELP | Cybin Inc | Stock-Other | 1.82% | +3.14% | — | |
| 15 | ARGX | Argenx Se - Adr | Stock-Healthcare | 1.69% | +0.29% | — | |
| 16 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 1.54% | +1.20% | — | |
| 17 | RXRX | Recursion Pharmaceuticals-a | Stock-Healthcare | 1.51% | +0.15% | — | |
| 18 | INSM | Insmed Inc | Stock-Healthcare | 0.89% | -0.36% | — | |
| 19 | ETHA | Ishares Ethereum Trust ETF | ETF-Other | 0.66% | -0.20% | — | |
| 20 | HRMY | Harmony Biosciences Holdings | Stock-Other | 0.62% | +0.13% | — | |
| 21 | TRDA | Entrada Therapeutics Inc | Stock-Other | 0.51% | -0.24% | — | |
| 22 | IBIT | Ishares Bitcoin Trust ETF | ETF-Crypto | 0.51% | -0.11% | — | |
| 23 | RANI | Rani Therapeutics Holdings-a | Stock-Other | 0.30% | -0.01% | — | |
| 24 | BOLT | Bolt Biotherapeutics Inc | Stock-Other | 0.10% | -0.09% | -49.87% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | LBRX | Lb Pharmaceuticals Inc | +6.8% | +110.22% | Add |
| 2 | EVMN | Evommune Inc | +5.2% | — | Unchanged |
| 3 | MPLT | Maplight Therapeutics Inc | +1% | — | Unchanged |
| 4 | RVMD | Revolution Medicines Inc | +0.2% | — | Unchanged |
| 5 | TRDA | Entrada Therapeutics Inc | +0.1% | — | Unchanged |
| 6 | ASND | Ascendis Pharma A/S | 0% | — | Unchanged |
| 7 | KYMR | Kymera Therapeutics Inc | 0% | — | Unchanged |
| 8 | BOLT | Bolt Biotherapeutics Inc | -0.2% | -49.87% | Trim |
| 9 | IBIT | Ishares Bitcoin Trust ETF | -0.2% | — | Unchanged |
| 10 | HRMY | Harmony Biosciences Holdings | -0.3% | — | Unchanged |
| 11 | RANI | Rani Therapeutics Holdings-a | -0.3% | — | Unchanged |
| 12 | ETHA | Ishares Ethereum Trust ETF | -0.4% | — | Unchanged |
| 13 | ARGX | Argenx Se - Adr | -0.4% | — | Unchanged |
| 14 | ONC | Beone Medicines Ltd-adr | -0.4% | — | Unchanged |
| 15 | ACAD | Acadia Pharmaceuticals Inc | -0.6% | — | Unchanged |
| 16 | RXRX | Recursion Pharmaceuticals-a | -0.7% | — | Unchanged |
| 17 | PCOR | Procore Technologies Inc | -1% | — | Unchanged |
| 18 | INCY | Incyte CORP | -1.1% | -8.95% | Trim |
| 19 | RYTM | Rhythm Pharmaceuticals Inc | -1.2% | — | Unchanged |
| 20 | OCS | Oculis Holding AG | -1.5% | -31.85% | Trim |
| 21 | HELP | Cybin Inc | -1.6% | — | Unchanged |
| 22 | MDGL | Madrigal Pharmaceuticals Inc | -3.7% | -52.22% | Trim |
| 23 | CELC | Celcuity Inc | — | NEW | New buy |
| 24 | LAB | Standard Biotools Inc | — | EXIT | Sold out |
| 25 | INSM | Insmed Inc | — | NEW | New buy |
| 26 | REPL | Replimune Group Inc | — | EXIT | Sold out |
| 27 | BCYC | Bicycle Therapeutics Plc-adr | — | EXIT | Sold out |
| 28 | RKLB | Rocket Lab CORP | — | EXIT | Sold out |
| 29 | BSLK | Bolt Projects Holdings Inc | — | EXIT | Sold out |
According to official SEC Form 13F filings, Nan Fung Group Holdings Ltd reported a total U.S. public equity portfolio value of $131.5M across 24 disclosed positions in Q1 2026.
During Q1 2026, Nan Fung Group Holdings Ltd's top holdings by market value included EVMN (27.3%)、MPLT (16.3%)、LBRX (12.8%). The largest single position, EVMN, represented 27.3% of total portfolio value.
In Q1 2026, Nan Fung Group Holdings Ltd made 12 total portfolio adjustments, initiating 2 new buys, adding to 1 positions, trimming 4 holdings, and fully liquidating 5 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.